Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-02-28

Study Completion Date

2027-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This will be a prospective, cluster-randomized, crossover, non-inferiority trial of 250 participants within 48 hours of an inpatient admission for heart failure or emergency department presentation for heart failure with plans for admission or observation/short-stay hospitalization comparing early discharge using subcutaneous furosemide to standard inpatient care. Individual practice groups will serve as "clusters" and the unit of randomization. Each participating cluster will implement either the early discharge strategy using the intervention or standard care for initial two-month blocks, followed by a crossover to the alternate strategy. The primary outcome is days alive and out of hospital at 30 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hypertonic Saline Therapy in Ambulatory Heart Failure Unit.

NCT04533997

Heart Failure

COMPLETED PHASE3

Ultrafiltration Versus Intravenous (IV) Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure: (UNLOAD)

NCT00124137

Congestive Heart Failure

COMPLETED NA

Forced Fluid Removal in High Risk Acute Kidney Injury

NCT02458157

Acute Kidney Injury Fluid Overload Critical Illness

TERMINATED PHASE4

Volume Optimization Incorporating Negative Pressure Diuresis in Heart Failure (VOID-HF)

NCT04227977

Cardiorenal Syndrome

COMPLETED NA

Controlled Fluid Removal in Critical Ill Patients With Fluid Overload in the Intensive Care Unit.

NCT04180397

Fluid Overload

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

HF contributes to over 1 million emergency department visits and nearly 1 million hospitalizations annually. The estimated annual mean cost per person with HF was $32,955 in 2017-2018, with the majority of costs due to hospitalization. The current standard of care typically involves admission for intravenous (IV) diuretics, monitoring for adequate decongestion, transition to oral diuretics, and discharge once clinical stability is achieved. The median length of stay for HF hospitalizations in the United States is 5 days but varies significantly across health systems and at the patient level. Extended hospitalizations, while traditionally considered necessary for complete decongestion, carry substantial risks, including increased risk of all-cause death and readmission. Patients experience deconditioning and increased frailty and are at risk for hospital-acquired complications, including infections, falls, and cognitive decline. Furthermore, prolonged hospitalization can lead to post-hospital syndrome, characterized by increased vulnerability and risk for adverse events in the immediate post-discharge period. For these reasons, reducing length of stay has emerged as a critical goal in HF management, aimed at both decreasing costs and improving patient outcomes by minimizing hospital-related complications and preserving quality of life.

Recent developments in subcutaneous furosemide formulations offer a potential solution to this clinical challenge. Pharmacokinetic studies demonstrate that subcutaneous furosemide achieves bioavailability comparable to IV administration and superior to oral formulations. The consistent absorption profile and reliable bioavailability of subcutaneous furosemide, combined with its ease of administration, presents an opportunity to provide hospital-level diuresis in the outpatient setting. This could enable earlier discharge while maintaining the intensity of diuretic therapy needed for complete decongestion. However, a critical knowledge gap exists regarding the safety and efficacy of an early discharge strategy utilizing subcutaneous furosemide compared to traditional inpatient management.

This trial aims to address this knowledge gap through a cluster-randomized crossover study comparing early discharge with subcutaneous furosemide to standard inpatient care and receipt of IV furosemide. By implementing standardized protocols across two major health systems, the investigators will evaluate whether this novel approach can safely reduce length of stay while maintaining clinical outcomes. The study design accounts for institutional variations in care delivery while providing robust data on safety, efficacy, and resource utilization. Results from this trial could fundamentally change the management paradigm for acute heart failure hospitalizations, potentially improving both healthcare efficiency and patient outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Acute Decompensated Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomization at the cluster level (hospitalist subgroups, academic teaching teams, and cardiology practice groups). Each participating cluster will implement either the early discharge strategy or standard care for initial two-month blocks, followed by a crossover to the alternate strategy.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Early Discharge with Subcutaneous Furosemide

The practice group randomized to early discharge with subcutaneous furosemide home infusion will begin initiation of subcutaneous furosemide (LASIX-ONYU) with a SQIN-Infusor device prior to discharge from the hospital. Dosing will be based on pre-admission oral furosemide requirements. Those with a home dose of ≤80mg/day oral furosemide will receive 80mg subcutaneous once daily at home and those with \>80mg/day oral furosemide will receive 80mg subcutaneous twice daily at home.

Group Type EXPERIMENTAL

Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor

Intervention Type COMBINATION_PRODUCT

Each practice group randomized to early discharge with subcutaneous furosemide will provide the patient with prefilled units of Lasix® ONYU furosemide injection containing 80 mg per 2.67 mL in a single-dose prefilled cartridge co-packaged with a single-use Disposable Unit of the Infusor that will be used in conjunction with the reusable unit of the Lasix ONYU Infusor. Dosing based on pre-admission oral furosemide requirements: ≤80mg/day oral furosemide will be given 80mg subcutaneous once daily or \>80mg/day oral furosemide will be given 80mg subcutaneous twice daily. Dosing will be continued until clinical euvolemia is reached.

Usual Care

Usual inpatient care with IV furosemide. Discharge timing determined by treating physician per standard practice.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor

Each practice group randomized to early discharge with subcutaneous furosemide will provide the patient with prefilled units of Lasix® ONYU furosemide injection containing 80 mg per 2.67 mL in a single-dose prefilled cartridge co-packaged with a single-use Disposable Unit of the Infusor that will be used in conjunction with the reusable unit of the Lasix ONYU Infusor. Dosing based on pre-admission oral furosemide requirements: ≤80mg/day oral furosemide will be given 80mg subcutaneous once daily or \>80mg/day oral furosemide will be given 80mg subcutaneous twice daily. Dosing will be continued until clinical euvolemia is reached.

Intervention Type COMBINATION_PRODUCT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

subcutaneous furosemide

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Within 48 hours of inpatient stay OR ED presentation for HF with plans for admission OR observation stay/short-stay hospitalization for HF
* Expected to require at least 24 additional hours of IV diuretics
* Adequate home environment for self-care
* Patient or caregiver capable of operating subcutaneous delivery device

Exclusion Criteria

* Cognitive impairment preventing informed consent
* Geographic barriers to follow-up
* Pregnancy or breastfeeding
* IV furosemide requirement \>250mg/day
* eGFR \<20 mL/min/1.73m2
* Type 1 myocardial infarction during index admission
* End-stage HF with receipt or consideration of heart transplant or LVAD or requiring inotropic or mechanical circulatory support
* Potassium \<3.0 or \>6.0 mmol/L or sodium \<125 mmol/L

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No